Abstract

Pharmaceutical nanotechnology has revolutionized drug delivery by enabling precise control over therapeutic agent distribution, release kinetics, and site-specific targeting. Conventional drug formulations often suffer from poor bioavailability, rapid clearance, systemic toxicity, and inability to reach specific therapeutic targets, necessitating the development of advanced nanocarrier systems. This review examines emerging trends in pharmaceutical nanotechnology focusing on controlled, targeted, and sustained drug release applications. Various nanocarrier platforms including polymeric nanoparticles, liposomes, solid lipid nanoparticles, dendrimers, carbon-based nanomaterials, and inorganic nanoparticles are discussed with emphasis on their design principles and therapeutic applications. The mechanisms underlying controlled release kinetics, active and passive targeting strategies, and sustained delivery approaches are critically analyzed. Significant advances in cancer chemotherapy, gene therapy, antimicrobial treatments, and management of chronic diseases demonstrate the clinical potential of these nanotechnological platforms. Despite remarkable progress, challenges including scalability, regulatory approval, long-term safety profiles, and manufacturing reproducibility remain substantial barriers to clinical translation. Future perspectives highlight the integration of stimuli-responsive systems, personalized nanomedicine, and artificial intelligence-guided design as promising directions. This review provides a comprehensive overview of current pharmaceutical nanotechnology landscape and identifies critical research priorities for advancing controlled and targeted drug delivery systems toward widespread clinical implementation.